{"DataElement":{"publicId":"10380424","version":"1","preferredName":"Tumor/Lesion Identification Supplemental Qualifiers Dataset WHO Classification of Tumors Acute Myeloid Leukemia Category","preferredDefinition":"World Health Organization disease classification on acute myeloid leukemia.","longName":"SUPPTU_QVAL_TUAMLWHO","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"10380342","version":"1","preferredName":"Tumor/Lesion Identification Supplemental Qualifiers Dataset WHO Classification of Tumors Acute Myeloid Leukemia","preferredDefinition":"_A dataset containing supplemental information, specifically non-standard variables, to parent records in the tumor/lesion identification domain:A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings._A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","longName":"10379801v1.00:10380341v1.00","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"10379801","version":"1","preferredName":"Tumor/Lesion Identification Supplemental Qualifiers Dataset","preferredDefinition":"A dataset containing supplemental information, specifically non-standard variables, to parent records in the tumor/lesion identification domain.","longName":"C147264","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor/Lesion Identification Supplemental Qualifiers Dataset","conceptCode":"C147264","definition":"A dataset containing supplemental information, specifically non-standard variables, to parent records in the tumor/lesion identification domain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-94F1-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-05-26","endDate":null,"createdBy":"LISU","dateCreated":"2022-05-26","modifiedBy":"LISU","dateModified":"2022-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"10380341","version":"1","preferredName":"WHO Classification of Tumors Acute Myeloid Leukemia","preferredDefinition":"A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings._A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","longName":"C113304:C3171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Classification of Tumors","conceptCode":"C113304","definition":"A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-9521-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-05-26","endDate":null,"createdBy":"LISU","dateCreated":"2022-05-26","modifiedBy":"LISU","dateModified":"2022-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-9522-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-05-26","endDate":null,"createdBy":"LISU","dateCreated":"2022-05-26","modifiedBy":"RAGUNATHANU","dateModified":"2022-06-08","changeDescription":null,"administrativeNotes":"Created for COG PEPN2113 study. -SL","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3257021","version":"1","preferredName":"World Health Organization Acute Myeloid Leukemia Category","preferredDefinition":"A United Nations agency established to coordinate international health activities and to help governments improve health services._A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003_Category; used informally to mean a class of things.","longName":"3257021v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"150","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"AML with myelodysplasia-related changes","valueDescription":"Acute Myeloid Leukemia with Myelodysplasia-Related Changes","ValueMeaning":{"publicId":"3257022","version":"1","preferredName":"Acute Myeloid Leukemia with Myelodysplasia-Related Changes","longName":"3257022","preferredDefinition":"An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities. There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the cytogenetic abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia, Myelodysplasia-Related","conceptCode":"C7600","definition":"An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities.  There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the molecular abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A07C-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A095-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"Acute panmyelosis with myelofibrosis","valueDescription":"Acute Panmyelosis with Myelofibrosis","ValueMeaning":{"publicId":"2836784","version":"1","preferredName":"Acute Panmyelosis with Myelofibrosis","longName":"2836784","preferredDefinition":"An acute myeloid leukemia characterized by bone marrow fibrosis without preexisting primary myelofibrosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Panmyelosis with Myelofibrosis","conceptCode":"C4344","definition":"An acute myeloid leukemia characterized by bone marrow fibrosis without preexisting primary myelofibrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-67F2-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A0A9-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"Acute basophilic leukemia","valueDescription":"Acute Basophilic Leukemia","ValueMeaning":{"publicId":"2836779","version":"1","preferredName":"Acute Basophilic Leukemia","longName":"2836779","preferredDefinition":"A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Basophilic Leukemia","conceptCode":"C3164","definition":"A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-677E-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"COOPERM","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A0BE-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"Acute megakaryoblastic leukemia","valueDescription":"Acute Megakaryoblastic Leukemia","ValueMeaning":{"publicId":"2558163","version":"1","preferredName":"Acute Megakaryoblastic Leukemia","longName":"2558163","preferredDefinition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Megakaryoblastic Leukemia","conceptCode":"C3170","definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B040-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A0C8-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"Erythroleukemia, erythroid/myeloid","valueDescription":"Erythroleukemia","ValueMeaning":{"publicId":"3257024","version":"1","preferredName":"Erythroleukemia","longName":"3257024","preferredDefinition":"Acute erythroid leukemia characterised by the presence of at least 50% erythroid precursors and at least 20% myeloblasts in the bone marrow. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythroleukemia","conceptCode":"C7152","definition":"Acute erythroid leukemia characterised by the presence of at least 50% erythroid precursors and at least 20% myeloblasts in the bone marrow.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A0D5-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A0EE-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"Acute erythroid leukemia","valueDescription":"Acute Erythroid Leukemia","ValueMeaning":{"publicId":"2836778","version":"1","preferredName":"Acute Erythroid Leukemia","longName":"2836778","preferredDefinition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Erythroid Leukemia","conceptCode":"C8923","definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-675B-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A102-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"Acute monoblastic/monocytic leukemia","valueDescription":"Acute Monoblastic Leukemia and Acute Monocytic Leukemia","ValueMeaning":{"publicId":"2672724","version":"1","preferredName":"Acute Monoblastic Leukemia and Acute Monocytic Leukemia","longName":"2672724","preferredDefinition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage.  Bleeding disorders are common presenting features.  It usually follows an aggressive clinical course.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Monoblastic and Monocytic Leukemia","conceptCode":"C7318","definition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37BD0487-E0F4-6FAB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A116-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"Acute myelomonocytic leukemia","valueDescription":"Acute Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2836785","version":"1","preferredName":"Acute Myelomonocytic Leukemia","longName":"2836785","preferredDefinition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myelomonocytic Leukemia","conceptCode":"C7463","definition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-6815-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A12A-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"AML with maturation","valueDescription":"Acute Myeloid Leukemia with Maturation","ValueMeaning":{"publicId":"2836809","version":"1","preferredName":"Acute Myeloid Leukemia with Maturation","longName":"2836809","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Maturation","conceptCode":"C3250","definition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246BA48-A992-2000-E040-BB89AD437D62","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A13E-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"AML without maturation","valueDescription":"Acute Myeloid Leukemia without Maturation","ValueMeaning":{"publicId":"2836808","version":"1","preferredName":"Acute Myeloid Leukemia without Maturation","longName":"2836808","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia without Maturation","conceptCode":"C3249","definition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246BA48-A96F-2000-E040-BB89AD437D62","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A153-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"AML with minimal differentiation","valueDescription":"Acute Myeloid Leukemia, Minimally Differentiated","ValueMeaning":{"publicId":"2836807","version":"1","preferredName":"Acute Myeloid Leukemia, Minimally Differentiated","longName":"2836807","preferredDefinition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry.  The myeloid origin of the blasts is demonstrated by immunohistochemistry and/or electron microscopic studies.  The patients present with anemia, neutropenia, and thrombocytopenia.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Minimal Differentiation","conceptCode":"C8460","definition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246291A-4BDF-4EA6-E040-BB89AD432443","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A168-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"AML with mutated CEBPA","valueDescription":"Acute Myeloid Leukemia with Mutated CEBPA","ValueMeaning":{"publicId":"3257026","version":"1","preferredName":"Acute Myeloid Leukemia with Mutated CEBPA","longName":"3257026","preferredDefinition":"An acute myeloid leukemia with mutation of the CEBPA gene. It is usually associated with normal karyotype and most cases meet the criteria for acute myeloid leukemia with or without maturation. Cases with normal karyotype have a favorable prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with CEBPA Mutation","conceptCode":"C82433","definition":"An acute myeloid leukemia with non-germline mutations of the CEBPA gene.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A176-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A18F-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"AML with mutated NPM1","valueDescription":"Acute Myeloid Leukemia with Mutated NPM1","ValueMeaning":{"publicId":"3257028","version":"1","preferredName":"Acute Myeloid Leukemia with Mutated NPM1","longName":"3257028","preferredDefinition":"An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with NPM1 Mutation","conceptCode":"C82431","definition":"An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A19C-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A1B5-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"AML (megakaryoblastic) with t(1;22) (p13;q13); RBM15-MKL1","valueDescription":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1","ValueMeaning":{"publicId":"3257030","version":"1","preferredName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1","longName":"3257030","preferredDefinition":"An acute myeloid leukemia associated with t(1;22)(p13;q13) resulting in the expression of RBM15-MKL1 fusion protein. It affects infants and children and usually shows megakaryocytic maturation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1","conceptCode":"C82427","definition":"An acute myeloid leukemia associated with t(1;22)(p13.3;q13.1) resulting in the expression of RBM15-MKL1 fusion protein. It affects infants and children and usually shows megakaryocytic maturation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A1C2-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A1DB-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"AML with inv(3)(q21;q26.2) or t(3;3) (q21;q26.2);RPNI-EVI1","valueDescription":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","ValueMeaning":{"publicId":"3257032","version":"1","preferredName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","longName":"3257032","preferredDefinition":"An acute myeloid leukemia associated with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","conceptCode":"C82426","definition":"An acute myeloid leukemia associated with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A1E8-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A201-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"AML with t(6;9)(p23;q34);DEK-NUP214","valueDescription":"Acute Myeloid Leukemia with t(6;9)(p23;q34.1); DEK-NUP214","ValueMeaning":{"publicId":"3257034","version":"1","preferredName":"Acute Myeloid Leukemia with t(6;9)(p23;q34.1); DEK-NUP214","longName":"3257034","preferredDefinition":"An acute myeloid leukemia associated with t(6;9)((p23;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214","conceptCode":"C82423","definition":"An acute myeloid leukemia associated with t(6;9)(p22.3;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A20E-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A227-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"AML with t(9;11)(p22;q33);MLLT3-MLL","valueDescription":"Acute Myeloid Leukemia with t(9;11)(p22;q23); MLLT3-MLL","ValueMeaning":{"publicId":"3257036","version":"1","preferredName":"Acute Myeloid Leukemia with t(9;11)(p22;q23); MLLT3-MLL","longName":"3257036","preferredDefinition":"An acute myeloid leukemia associated with t(9;11)(p22;q23) and MLLT3 (AF9)-MLL fusion protein expression.  Morphologically it usually has monocytic features.  It may present at any age but it is more commonly seen in children.  Patients may present with disseminated intravascular coagulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","conceptCode":"C82403","definition":"An acute myeloid leukemia associated with t(9;11)(p21.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A234-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A24D-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"AML with inv(16)(p13q22) or t(16;16) (p13.1;q22), (CBF&#946;/MYH11)","valueDescription":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","ValueMeaning":{"publicId":"3257038","version":"1","preferredName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","longName":"3257038","preferredDefinition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) which results in the expression of the fusion protein CBFB-MYH11.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","conceptCode":"C9018","definition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) which results in the expression of the fusion protein CBFB-MYH11.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A25A-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A273-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"AML with t(8;21)(q22;q22), RUNX1 RUNX1T1","valueDescription":"AML1-ETO Fusion Protein Expression","ValueMeaning":{"publicId":"3257039","version":"1","preferredName":"AML1-ETO Fusion Protein Expression","longName":"3257039","preferredDefinition":"A fusion gene (~4.3 kb) that results from a chromosomal translocation t(8;21)(q22;q22) which fuses the first 5 exons of the RUNX1 gene to exon 2 of the RUNX1T1 gene. This rearrangement is associated with acute myeloid leukemia.::1: A fusion protein (752 aa, ~83 kDa) encoded by the RUNX1/RUNX1T1 fusion gene. This protein is comprised of the N-terminal runt domain of the runt-related transcription factor 1 protein fused to the 577 C-terminal residues of protein CBFA2T1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RUNX1/RUNX1T1 Fusion Gene","conceptCode":"C99294","definition":"A fusion gene (~4.3 kb) that results from a chromosomal translocation t(8;21)(q22;q22) which fuses the first 5 exons of the RUNX1 gene to exon 2 of the RUNX1T1 gene. This rearrangement is associated with acute myeloid leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"RUNX1/RUNX1T1 Fusion Protein","conceptCode":"C19892","definition":"A fusion protein (752 aa, ~83 kDa) encoded by the RUNX1/RUNX1T1 fusion gene. This protein is comprised of the N-terminal runt domain of the runt-related transcription factor 1 protein fused to the 577 C-terminal residues of protein CBFA2T1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A27D-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A296-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"Classified by FAB Only","valueDescription":"French-American-British Classification","ValueMeaning":{"publicId":"3257040","version":"1","preferredName":"French-American-British Classification","longName":"3257040","preferredDefinition":"A classification system for acute myeloid leukemias, acute lymphoblastic leukemias, and myelodysplastic syndromes. It is based on the morphologic and cytochemical evaluation of bone marrow and peripheral blood smears.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"French-American-British Classification","conceptCode":"C91220","definition":"A classification system for acute myeloid leukemias, acute lymphoblastic leukemias, and myelodysplastic syndromes.  It is based on the morphologic and cytochemical evaluation of bone marrow and peripheral blood smears.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A2A2-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A89D3C60-A2BB-6E25-E040-BB89AD433A3A","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","deletedIndicator":"No"},{"value":"Blastic plasmacytoid dendritic cell neoplasm","valueDescription":"Blastic Plasmacytoid Dendritic Cell Neoplasm","ValueMeaning":{"publicId":"4858051","version":"1","preferredName":"Acute Undifferentiated Leukemia","longName":"4858051v1.00","preferredDefinition":"A rare acute leukemia of ambiguous lineage in which the blasts do not express markers specific to myeloid or lymphoid lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Undifferentiated Leukemia","conceptCode":"C9298","definition":"A rare acute leukemia of ambiguous lineage in which the blasts do not express markers specific to myeloid or lymphoid lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1805D4A1-419B-4FE2-E050-BB89AD435E9B","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1805D4A1-41B4-4FE2-E050-BB89AD435E9B","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"ONEDATA","dateModified":"2015-06-08","deletedIndicator":"No"},{"value":"Myeloid leukemia associated with Down syndrome","valueDescription":"Myeloid Leukemia Associated with Down Syndrome","ValueMeaning":{"publicId":"4858053","version":"1","preferredName":"Myeloid Leukemia Associated with Down Syndrome","longName":"4858053","preferredDefinition":"Acute myeloid leukemia or myelodysplastic syndrome occurring in children with Down syndrome.  The acute myeloid leukemia is usually an acute megakaryoblastic leukemia, and is associated with GATA1 gene mutation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid Leukemia Associated with Down Syndrome","conceptCode":"C43223","definition":"Acute myeloid leukemia or myelodysplastic syndrome occurring in children with Down syndrome.  The acute myeloid leukemia is usually an acute megakaryoblastic leukemia, and is associated with GATA1 gene mutation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1805D4A1-41C1-4FE2-E050-BB89AD435E9B","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1805D4A1-41DA-4FE2-E050-BB89AD435E9B","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"ONEDATA","dateModified":"2015-06-08","deletedIndicator":"No"},{"value":"Transient abnormal myelopoiesis","valueDescription":"Transient Abnormal Myelopoiesis","ValueMeaning":{"publicId":"4858055","version":"1","preferredName":"Transient Abnormal Myelopoiesis","longName":"4858055","preferredDefinition":"A myeloid proliferation occurring in newborns with Down syndrome.  It is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations.  The blasts display morphologic and immunophenotypic features of megakaryocytic lineage.  In the majority of patients the myeloid proliferation undergoes spontaneous remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transient Abnormal Myelopoiesis Associated with Down Syndrome","conceptCode":"C82339","definition":"A myeloid proliferation occurring in newborns with Down syndrome.  It is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations.  The blasts display morphologic and immunophenotypic features of megakaryocytic lineage.  In the majority of patients the myeloid proliferation undergoes spontaneous remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1805D4A1-41E7-4FE2-E050-BB89AD435E9B","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1805D4A1-4200-4FE2-E050-BB89AD435E9B","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"ONEDATA","dateModified":"2015-06-08","deletedIndicator":"No"},{"value":"Myeloid sarcoma","valueDescription":"Myeloid Sarcoma","ValueMeaning":{"publicId":"2559301","version":"1","preferredName":"Myeloid Sarcoma","longName":"2559301","preferredDefinition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid Sarcoma","conceptCode":"C3520","definition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B4B2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1805D4A1-420A-4FE2-E050-BB89AD435E9B","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"ONEDATA","dateModified":"2015-06-08","deletedIndicator":"No"},{"value":"Pure erythroid leukemia","valueDescription":"Pure Erythroid Leukemia","ValueMeaning":{"publicId":"4858057","version":"1","preferredName":"Pure Erythroid Leukemia","longName":"4858057","preferredDefinition":"Acute erythroid leukemia characterised by the presence of immature erythroid cells in the bone marrow (at least 80% of the cellular component), without evidence of a significant myeloblastic cell population present. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pure Erythroid Leukemia","conceptCode":"C7467","definition":"Acute erythroid leukemia characterized by the presence of immature erythroid cells in the bone marrow (at least 80% of the cellular component), without evidence of a significant myeloblastic cell population present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1805D4A1-4217-4FE2-E050-BB89AD435E9B","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1805D4A1-4230-4FE2-E050-BB89AD435E9B","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"ONEDATA","dateModified":"2015-06-08","deletedIndicator":"No"},{"value":"Therapy-related myeloid neoplasms","valueDescription":"Therapy-Related Acute Myeloid Leukemia","ValueMeaning":{"publicId":"4858058","version":"1","preferredName":"Therapy-Related Acute Myeloid Leukemia","longName":"4858058","preferredDefinition":"An acute myeloid leukemia arising as a result of the mutagenic effect of chemotherapy agents and/or ionizing radiation.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia Post Cytotoxic Therapy","conceptCode":"C8252","definition":"An acute myeloid leukemia arising as a result of the mutagenic effect of chemotherapy agents and/or ionizing radiation.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1805D4A1-423A-4FE2-E050-BB89AD435E9B","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1805D4A1-4252-4FE2-E050-BB89AD435E9B","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"ONEDATA","dateModified":"2015-06-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with myelodysplasia-related changes","valueDescription":"Acute Myeloid Leukemia with Myelodysplasia-Related Changes","ValueMeaning":{"publicId":"4858059","version":"1","preferredName":"Acute Myeloid Leukemia with Myelodysplasia-Related Changes","longName":"4858059","preferredDefinition":"An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities.  There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the cytogenetic abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia, Myelodysplasia-Related","conceptCode":"C7600","definition":"An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities.  There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the molecular abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1805D4A1-425D-4FE2-E050-BB89AD435E9B","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1805D4A1-4275-4FE2-E050-BB89AD435E9B","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"ONEDATA","dateModified":"2015-06-08","deletedIndicator":"No"},{"value":"Provisional entity: AML with mutated CEBPA","valueDescription":"Acute Myeloid Leukemia with Mutated CEBPA","ValueMeaning":{"publicId":"3257026","version":"1","preferredName":"Acute Myeloid Leukemia with Mutated CEBPA","longName":"3257026","preferredDefinition":"An acute myeloid leukemia with mutation of the CEBPA gene. It is usually associated with normal karyotype and most cases meet the criteria for acute myeloid leukemia with or without maturation. Cases with normal karyotype have a favorable prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with CEBPA Mutation","conceptCode":"C82433","definition":"An acute myeloid leukemia with non-germline mutations of the CEBPA gene.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A176-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1805D4A1-428A-4FE2-E050-BB89AD435E9B","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"ONEDATA","dateModified":"2015-06-08","deletedIndicator":"No"},{"value":"Provisional entity: AML with mutated NPM1","valueDescription":"Acute Myeloid Leukemia with Mutated NPM1","ValueMeaning":{"publicId":"3257028","version":"1","preferredName":"Acute Myeloid Leukemia with Mutated NPM1","longName":"3257028","preferredDefinition":"An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with NPM1 Mutation","conceptCode":"C82431","definition":"An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A19C-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1805D4A1-429E-4FE2-E050-BB89AD435E9B","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"ONEDATA","dateModified":"2015-06-08","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia, other or unclassifiable","valueDescription":"Acute Myeloid Leukemia Not Otherwise Specified","ValueMeaning":{"publicId":"4917551","version":"1","preferredName":"Acute Myeloid Leukemia Not Otherwise Specified","longName":"4917551","preferredDefinition":"Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia Not Otherwise Specified","conceptCode":"C27753","definition":"Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B7F62E5-D5E5-1CE6-E050-BB89AD4312A8","latestVersionIndicator":"Yes","beginDate":"2015-07-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-07-22","modifiedBy":"KUMMEROA","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B7F62E5-D5FD-1CE6-E050-BB89AD4312A8","beginDate":"2015-07-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-07-22","modifiedBy":"ONEDATA","dateModified":"2015-07-22","deletedIndicator":"No"},{"value":"Acute Promyelocytic Leukemia","valueDescription":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA","ValueMeaning":{"publicId":"4722782","version":"1","preferredName":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA","longName":"4722782","preferredDefinition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate.  It is characterized by the t(15;17)(q22;q12) translocation.  There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","conceptCode":"C3182","definition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the PML-RARA fusion. There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-22C4-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B7F62E5-D612-1CE6-E050-BB89AD4312A8","beginDate":"2015-07-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-07-22","modifiedBy":"ONEDATA","dateModified":"2015-07-22","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia with t(8;21)(q22,q22);RUNX1-RUNX1T1 (formerly known as AML1-ETO Fusion Protein Expression)","valueDescription":"Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1","ValueMeaning":{"publicId":"4917552","version":"1","preferredName":"Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1","longName":"4917552","preferredDefinition":"An acute myeloid leukemia (AML) showing maturation in the neutrophil lineage.  The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules.  This type of AML is associated with good response to chemotherapy and high complete remission rate.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1","conceptCode":"C9288","definition":"An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B7F62E5-D61C-1CE6-E050-BB89AD4312A8","latestVersionIndicator":"Yes","beginDate":"2015-07-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-07-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B7F62E5-D635-1CE6-E050-BB89AD4312A8","beginDate":"2015-07-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-07-22","modifiedBy":"ONEDATA","dateModified":"2015-07-22","deletedIndicator":"No"},{"value":"AML with recurrent genetic abnormalities","valueDescription":"Acute Myeloid Leukemia With Recurrent Genetic Abnormalities","ValueMeaning":{"publicId":"7110813","version":"1","preferredName":"Acute Myeloid Leukemia With Recurrent Genetic Abnormalities","longName":"7110813","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).: Used to indicate the presence of something or someone.: occurring again.: A molecular or cytogenic abnormality which occurs in either human disease states or disease models.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Recurrent","conceptCode":"C14173","definition":"Occurring again.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Molecular Abnormality","conceptCode":"C3910","definition":"A molecular or cytogenetic abnormality which occurs in either human disease states or disease models.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A62CE43-33A7-71D9-E053-F662850A1EAA","latestVersionIndicator":"Yes","beginDate":"2019-12-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2019-12-23","modifiedBy":"MAESKEB","dateModified":"2019-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A62CE43-33C0-71D9-E053-F662850A1EAA","beginDate":"2019-12-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2019-12-23","modifiedBy":"ONEDATA","dateModified":"2019-12-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3257020","version":"1","preferredName":"World Health Organization Acute Myeloid Leukemia Category","preferredDefinition":"A United Nations agency established to coordinate international health activities and to help governments improve health services.:A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003:Category; used informally to mean a class of things.","longName":"C75419:C3171:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"World Health Organization","conceptCode":"C75419","definition":"A United Nations agency established to coordinate international health activities and to help governments improve health services.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A055-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"ONEDATA","dateModified":"2011-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A066-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"MAESKEB","dateModified":"2019-12-23","changeDescription":"Created for TCGA per request by T.Lichtenberg. mc 7/21/11 Released per Tara's approval. mc 7/27/11 Added 3 PVs for COG APEC14B1 Myeloid Leukemia On Study Form per request by E.Tsan. mc 7/22/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"AML World Health Organization (WHO) disease classification:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-1D22-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-05-26","endDate":null,"createdBy":"LISU","dateCreated":"2022-05-26","modifiedBy":"KUMMEROA","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":"05/26/2022: created for COG PEPN2113 study. SL","unresolvedIssues":null,"deletedIndicator":"No"}}